Journal article
Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials.
Abstract
BACKGROUND: Stroke is a leading cause of death in the industrialized world, and hypercholesterolemia may be a risk factor for stroke.
OBJECTIVE: To determine whether reducing cholesterol levels with HMGcoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors or other antilipidemic interventions reduces risk for nonfatal and fatal stroke.
Authors
Bucher HC; Griffith LE; Guyatt GH
Journal
Annals of Internal Medicine, Vol. 128, No. 2, pp. 89–95
Publisher
American College of Physicians
Publication Date
January 15, 1998
DOI
10.7326/0003-4819-128-2-199801150-00002
ISSN
1056-8751